Survival and functional outcome after treatment for primary base of tongue cancer: A comparison of definitive chemoradiotherapy versus surgery followed by adjuvant radiotherapy

Sangjoon Park, Yeona Cho, Jeongshim Lee, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Hye Ryun Kim, Ki Chang Keum, Kyung Ran Park, Chang Geol Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose The purpose of this study was to compare the clinical and functional outcomes in patients with primary base of tongue (BOT) cancer who received definitive radiotherapy (RT) or surgery followed by radiotherapy (SRT). Materials and Methods Between January 2002 and December 2016, 102 patients with stage I-IVB primary BOT cancer underwent either definitive RT (n=46) or SRT (n=56), and treatment outcomes were compared between two groups. The expression of p16 was also analyzed. Results The RT group had more patients with advanced T stage (T3-4) disease (58.7% vs. 35.7%, p=0.021) and who received chemotherapy (91.3% vs. 37.5%, p < 0.001) than the SRT group. At a median follow up of 36.9 months (range, 3.3 to 181.5 months), the 5-year overall survival (OS) and disease-free survival (DFS) were 75.5% and 68.7%, respectively. With respect to treatment group, the 5-year OS and DFS in the RT and SRT groups did not differ significantly (OS, 68.7% vs. 80.5%, p=0.601; DFS, 63.1% vs. 73.1%, p=0.653). In multivariate analysis, OS differed significantly according to p16 expression (p16-negative vs. p16- positive; hazard ratio [HR], 0.145; 95% confidence interval [CI], 0.025 to 0.853; p=0.033). Regarding DFS, p16 expression (p16-negative vs. p16-positive; HR, 0.164; 95% CI, 0.045 to 0.598; p=0.006) showed a significant effect in multivariate analysis. Functional defects (late grade ≥ 3 dysphagia or voice alteration) were more frequently reported in the SRT than in the RT group (16.1% vs. 2.2%, p=0.021). Conclusion Despite advanced disease, patients in the RT group showed comparable survival outcomes and better functional preservation than those in the SRT group.

Original languageEnglish
Pages (from-to)1214-1225
Number of pages12
JournalCancer Research and Treatment
Volume50
Issue number4
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

Tongue Neoplasms
Adjuvant Radiotherapy
Chemoradiotherapy
Radiotherapy
Survival
Disease-Free Survival
Multivariate Analysis
Confidence Intervals
Deglutition Disorders
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Park, Sangjoon ; Cho, Yeona ; Lee, Jeongshim ; Koh, Yoon Woo ; Kim, Se Heon ; Choi, Eun Chang ; Kim, Hye Ryun ; Keum, Ki Chang ; Park, Kyung Ran ; Lee, Chang Geol. / Survival and functional outcome after treatment for primary base of tongue cancer : A comparison of definitive chemoradiotherapy versus surgery followed by adjuvant radiotherapy. In: Cancer Research and Treatment. 2018 ; Vol. 50, No. 4. pp. 1214-1225.
@article{b6e8f771bec14a72905695489612731a,
title = "Survival and functional outcome after treatment for primary base of tongue cancer: A comparison of definitive chemoradiotherapy versus surgery followed by adjuvant radiotherapy",
abstract = "Purpose The purpose of this study was to compare the clinical and functional outcomes in patients with primary base of tongue (BOT) cancer who received definitive radiotherapy (RT) or surgery followed by radiotherapy (SRT). Materials and Methods Between January 2002 and December 2016, 102 patients with stage I-IVB primary BOT cancer underwent either definitive RT (n=46) or SRT (n=56), and treatment outcomes were compared between two groups. The expression of p16 was also analyzed. Results The RT group had more patients with advanced T stage (T3-4) disease (58.7{\%} vs. 35.7{\%}, p=0.021) and who received chemotherapy (91.3{\%} vs. 37.5{\%}, p < 0.001) than the SRT group. At a median follow up of 36.9 months (range, 3.3 to 181.5 months), the 5-year overall survival (OS) and disease-free survival (DFS) were 75.5{\%} and 68.7{\%}, respectively. With respect to treatment group, the 5-year OS and DFS in the RT and SRT groups did not differ significantly (OS, 68.7{\%} vs. 80.5{\%}, p=0.601; DFS, 63.1{\%} vs. 73.1{\%}, p=0.653). In multivariate analysis, OS differed significantly according to p16 expression (p16-negative vs. p16- positive; hazard ratio [HR], 0.145; 95{\%} confidence interval [CI], 0.025 to 0.853; p=0.033). Regarding DFS, p16 expression (p16-negative vs. p16-positive; HR, 0.164; 95{\%} CI, 0.045 to 0.598; p=0.006) showed a significant effect in multivariate analysis. Functional defects (late grade ≥ 3 dysphagia or voice alteration) were more frequently reported in the SRT than in the RT group (16.1{\%} vs. 2.2{\%}, p=0.021). Conclusion Despite advanced disease, patients in the RT group showed comparable survival outcomes and better functional preservation than those in the SRT group.",
author = "Sangjoon Park and Yeona Cho and Jeongshim Lee and Koh, {Yoon Woo} and Kim, {Se Heon} and Choi, {Eun Chang} and Kim, {Hye Ryun} and Keum, {Ki Chang} and Park, {Kyung Ran} and Lee, {Chang Geol}",
year = "2018",
month = "10",
day = "1",
doi = "10.4143/crt.2017.498",
language = "English",
volume = "50",
pages = "1214--1225",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "4",

}

Survival and functional outcome after treatment for primary base of tongue cancer : A comparison of definitive chemoradiotherapy versus surgery followed by adjuvant radiotherapy. / Park, Sangjoon; Cho, Yeona; Lee, Jeongshim; Koh, Yoon Woo; Kim, Se Heon; Choi, Eun Chang; Kim, Hye Ryun; Keum, Ki Chang; Park, Kyung Ran; Lee, Chang Geol.

In: Cancer Research and Treatment, Vol. 50, No. 4, 01.10.2018, p. 1214-1225.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Survival and functional outcome after treatment for primary base of tongue cancer

T2 - A comparison of definitive chemoradiotherapy versus surgery followed by adjuvant radiotherapy

AU - Park, Sangjoon

AU - Cho, Yeona

AU - Lee, Jeongshim

AU - Koh, Yoon Woo

AU - Kim, Se Heon

AU - Choi, Eun Chang

AU - Kim, Hye Ryun

AU - Keum, Ki Chang

AU - Park, Kyung Ran

AU - Lee, Chang Geol

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose The purpose of this study was to compare the clinical and functional outcomes in patients with primary base of tongue (BOT) cancer who received definitive radiotherapy (RT) or surgery followed by radiotherapy (SRT). Materials and Methods Between January 2002 and December 2016, 102 patients with stage I-IVB primary BOT cancer underwent either definitive RT (n=46) or SRT (n=56), and treatment outcomes were compared between two groups. The expression of p16 was also analyzed. Results The RT group had more patients with advanced T stage (T3-4) disease (58.7% vs. 35.7%, p=0.021) and who received chemotherapy (91.3% vs. 37.5%, p < 0.001) than the SRT group. At a median follow up of 36.9 months (range, 3.3 to 181.5 months), the 5-year overall survival (OS) and disease-free survival (DFS) were 75.5% and 68.7%, respectively. With respect to treatment group, the 5-year OS and DFS in the RT and SRT groups did not differ significantly (OS, 68.7% vs. 80.5%, p=0.601; DFS, 63.1% vs. 73.1%, p=0.653). In multivariate analysis, OS differed significantly according to p16 expression (p16-negative vs. p16- positive; hazard ratio [HR], 0.145; 95% confidence interval [CI], 0.025 to 0.853; p=0.033). Regarding DFS, p16 expression (p16-negative vs. p16-positive; HR, 0.164; 95% CI, 0.045 to 0.598; p=0.006) showed a significant effect in multivariate analysis. Functional defects (late grade ≥ 3 dysphagia or voice alteration) were more frequently reported in the SRT than in the RT group (16.1% vs. 2.2%, p=0.021). Conclusion Despite advanced disease, patients in the RT group showed comparable survival outcomes and better functional preservation than those in the SRT group.

AB - Purpose The purpose of this study was to compare the clinical and functional outcomes in patients with primary base of tongue (BOT) cancer who received definitive radiotherapy (RT) or surgery followed by radiotherapy (SRT). Materials and Methods Between January 2002 and December 2016, 102 patients with stage I-IVB primary BOT cancer underwent either definitive RT (n=46) or SRT (n=56), and treatment outcomes were compared between two groups. The expression of p16 was also analyzed. Results The RT group had more patients with advanced T stage (T3-4) disease (58.7% vs. 35.7%, p=0.021) and who received chemotherapy (91.3% vs. 37.5%, p < 0.001) than the SRT group. At a median follow up of 36.9 months (range, 3.3 to 181.5 months), the 5-year overall survival (OS) and disease-free survival (DFS) were 75.5% and 68.7%, respectively. With respect to treatment group, the 5-year OS and DFS in the RT and SRT groups did not differ significantly (OS, 68.7% vs. 80.5%, p=0.601; DFS, 63.1% vs. 73.1%, p=0.653). In multivariate analysis, OS differed significantly according to p16 expression (p16-negative vs. p16- positive; hazard ratio [HR], 0.145; 95% confidence interval [CI], 0.025 to 0.853; p=0.033). Regarding DFS, p16 expression (p16-negative vs. p16-positive; HR, 0.164; 95% CI, 0.045 to 0.598; p=0.006) showed a significant effect in multivariate analysis. Functional defects (late grade ≥ 3 dysphagia or voice alteration) were more frequently reported in the SRT than in the RT group (16.1% vs. 2.2%, p=0.021). Conclusion Despite advanced disease, patients in the RT group showed comparable survival outcomes and better functional preservation than those in the SRT group.

UR - http://www.scopus.com/inward/record.url?scp=85054765970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054765970&partnerID=8YFLogxK

U2 - 10.4143/crt.2017.498

DO - 10.4143/crt.2017.498

M3 - Article

C2 - 29281874

AN - SCOPUS:85054765970

VL - 50

SP - 1214

EP - 1225

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 4

ER -